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ABSTRACT
We present a new publicly accessible web-service,
RiboSoft, which implements a comprehensive ham-
merhead ribozyme design procedure. It accepts as
input a target sequence (and some design param-
eters) then generates a set of ranked hammerhead
ribozymes, which target the input sequence. This
paper describes the implemented procedure, which
takes into consideration multiple objectives lead-
ing to a multi-objective ranking of the computer-
generated ribozymes. Many ribozymes were assayed
and validated, including four ribozymes targeting the
transcript of a disease-causing gene (a mutant ver-
sion of PABPN1). These four ribozymes were suc-
cessfully tested in vitro and in vivo, for their ability
to cleave the targeted transcript. The wet-lab posi-
tive results of the test are presented here demon-
strating the real-world potential of both hammerhead
ribozymes and RiboSoft. RiboSoft is freely avail-
able at the website http://ribosoft.fungalgenomics.
ca/ribosoft/.
INTRODUCTION
There are many uses for hammerhead ribozymes (hhRz),
as they are short catalytic RNA molecules which anneal to
and cleave other RNA molecules––typically transcripts of
genes––leading to the knockdown of gene expression. There
are other means of gene suppression via transcript cleav-
age, and they include the widely used RNAi (1). RNAi is
effective at low concentrations, can be delivered viamultiple
pathways, allow for tissue specific expression and are gener-
ally accepted to be highly specific and non-toxic (2). Nev-
ertheless, ribozymes (3), including the hhRz (the focus of
this paper) (4), have relatively simple catalytic domains and
can be used to target specifically RNA. They can potentially
discriminate between single-base polymorphisms, target in-
trons and sub-cellular compartments, do not require helper
proteins to function and hence, can be tested in vitro (2).
They are also easily modifiable and have been modified in
ways that allow formore efficient (5,6), more specific (7,8) as
well as allosteric applications involving RNA (9), and small
molecules (10) or protein triggers (11). Finally, ribozymes
can work in organisms that lack the typical RNAi mecha-
nism found in eukaryotes, such as bacteria (12) or even in
simple solutions in vitro. For these reasons, hhRz are seen
as general and malleable means of transcript modification
and gene therapy (13), with applications in biosensors (10)
and synthetic biology as well (14).
The hhRz is one of several structural motifs of ri-
bozymes that can cause both cis- and trans-cleavage of
RNA molecules with certain properties (3). The model of
the hhRz, consists of three largely independent parts: stem
I, stem II (including the catalytic core) and stem III. A trans-
cleaving ribozyme annealed to a target substrate strand is
shown in Figure 1. Stems I and III are chosen to be com-
plementary to the substrate strand, which must include an
NUH triplet. Stem II is found next to the catalytic core’s
conserved GAAA and CUGANGA. Generally speaking, a
designer would pick an empirically proven stem II and cat-
alytic core, then vary the two ‘arms’ (call them I and III) so
they would form stems I and III, with pre-specified charac-
teristics, with the targeted substrate.
Both target specificity and turnover (re-use) rate of a
hhRz depend on the length and sequence of its two arms.
Optimal turnover requires that product dissociation not be
slow. For long substrates with extensive secondary struc-
ture, such is the case with most mRNAs, the optimal flank-
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Figure 1. Model of trans-acting hammerhead ribozyme used by RiboSoft.
Nucleotides in red correspond to the conserved catalytic core, other nu-
cleotides may vary. Nucleotides in blue are important for the tertiary in-
teraction between stems I and II. The sequence of stem II pictured here
corresponds to the optional extended hhRz model (39) used by RiboSoft
and includes the extra nucleotides in gray as well.
ing arms may be longer than 10 nt, but even in this case, in-
creasing the arms toomuch reduces turnaround rate greatly.
This paper introduces a web-service that makes it easy
for interested parties––not only ribozyme experts––to (i)
design hhRz that target a particular gene, or any RNA
sequence, and (ii) make an informed choice as to which
of the possible ribozymes are best for a particular appli-
cation. All this while automatically taking in account the
multiple variables that determine ribozyme efficacy (target
structure, ribozyme-target annealing and ribozyme struc-
ture, including the tertiary interaction of so-called extended
ribozymes). In addition, we have used this tool to design
hhRz, which were tested for efficient cleavage of three tran-
scripts, as well as in vivo for the PABPN1 gene, the root
cause of OPMD.
OPMD (Oculopharyngeal muscular dystrophy) is a late
onset (around 50 years old) muscle disease with occasional
involvement of the nervous system that can lead to oblig-
atory wheelchair usage (15,16). Genetically, diagnosis re-
quires detection of an expansion of a GCN trinucleotide
repeat in the first exon of PABPN1. Normal alleles contain
10 GCN trinucleotide repeats; autosomal dominant alleles
range in size from 12 to 17 GCN repeats; autosomal reces-
sive alleles comprise 11 GCN repeats (16).
Spinocerebellar ataxia type 3 (SCA3), like OPMD, is a
trinucleotide repeat neurodegenerative disease caused by
the polyglutamine (versus polyalanine) expansion in the
deubiquitinating enzyme, Ataxin-3 (ATXN3). Using the
RNA interference mechanism, Rodrı´guez-Lebro´n, E et al.
made microRNA mimics that targeted the 3′-untranslated
region of a human ATXN3 expressed in the cerebellum of
transgenic mice (17). This resulted in silencing of the hu-
man gene and cleared the abnormal nuclear accumulation
of the mutant protein. Most OPMD-afflicted patients have
a wild type PABPN1 allele and a mutant (disease-causing)
PABPN1 allele, so targeting the 3′-UTR of the mRNA of
PABPN1 (with microRNAs or ribozymes) will suppress
both alleles. Hu et al. (18) demonstrated that the targeting
of the trinucleotide repeats can preferentially inhibit mutant
ATXN3. However, an ideal solution is one that would exclu-
sively impact the mutant allele or compensate for the knock-
down effect on the wild type allele. This could be achieved
by cleaving both alleles with a hhRz and providing a re-
placement mRNA with sequence modification rendering it
immune to cleavage. HhRz were shown to efficiently sup-
press beta-secretase gene expression in HEK293 (human
embryonic kidney) cells (19). In the sequel, we show that
RiboSoft can generate the designs of active hhRz that were
proven effective in vitro and in vivo against PABPN1 se-
quence. We also tested a dozen ribozymes that proved ca-
pable of cleaving RFP or a 16S rRNA fragment in vitro.
Finally, we show that the combined use of ribozymes can
achieve near complete depletion of the target RNAs.
MATERIALS AND METHODS
RiboSoft usage
Before the design algorithm can run, valid input from the
user must be entered. The required input takes the form of
(i) a target nucleotide sequence, which may be provided by:
direct entry into a text box, uploading a pure text (.txt) or
FASTA format file, or typing in a GenBank sequence num-
ber (Figure 2); and (ii) a set of design parameter values (Fig-
ure 3).
The design parameters are: (i) the target environment:
whether it is in vitro or in vivo, and if it is in vivo, then the
name or code of the intended organism; (ii) environment
properties: temperature as well as oligomer, sodium and
magnesium ion concentrations; (iii) potential cut-sites (e.g.
GUC); (iv) ribozyme structure: minimal or extended (i.e.
involving loop-loop interaction, designated as wishbone-
shaped) (5); (v) advanced options: the minimum and maxi-
mum lengths of helices I and III (the targeting arms of the ri-
bozyme), the presence or absence of a T7 promoter (usually
used for in vitro experiments) and whether specificity should
take into consideration off-target sites that allow annealing
only or annealing and cleavage by the designed ribozyme.
After the parameters are chosen, they are displayed on a
summary page (Figure 4) before requesting the user’s email
to submit the ribozyme design request.
A target sequence must be provided, but most of the de-
sign parameters have default values, which are acceptable
for most applications. The design algorithm then initiates
the actual design and optimization procedure. This proce-
dure has six steps, which starts with the generation of a large
number of candidate ribozymes, assessing them using vari-
ousmeasures of quality, including (but not limited to) target
cut-site accessibility and specificity to the target sequence as
well as proper folding of the ribozyme structure. The pro-
cedure concludes with the multi-objective assessment and
ranking of resulting candidate ribozymes (Figure 5). The
algorithms for each part of the procedure are explained be-
low.
Candidate generation
In principle, a hhRz can cleave, with different efficiency
levels (measured by different studies with varying results
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Figure 2. Snapshot of the input screen (step 1) of RiboSoft: asking the user for a sequence, a file or a sequence code.
[20,21]), at locations on RNA strands with an NUH motif.
An RNA strand may have any number of different cut-sites
within it, repeated any number of times. The most widely
targeted cut-site is GUC, as it is thought to be the most sus-
ceptible to hhRz cleavage. For all cut-sites, all possible can-
didates with perfectly hybridizing arms, of lengths between
the minimum and maximum values specified by the user,
are generated. The total number of candidates is calculable
using the formula:
≈ (arm−length range)2 · (number of cut−si tes) (1)
This implies that the number of candidates is also propor-
tional to the target sequence length, sincemore cut-sites will
be found. To provide a rough estimate of the number of can-
didates that are typically generated byRiboSoft, with a con-
servative length of 3–10 for the hybridizing arms and two
cut-site types, a sequence of 3000 nucleotides yields about
100 cut-sites for two cut-site types for a total of 6400 ri-
bozyme candidates.
Annealing temperature
A trans-cleaving hhRz may be viewed as a three-part con-
struct: a fixed largely double-stranded central segment (core
and stem II), plus two single-stranded arms (stems I and III)
up- and down-stream of the core. It is those two arms that
provide the selectivity that permit the ribozyme to strongly
anneal to a particular site on a target RNA molecule
amongst myriad RNA strands in the medium and hence,
cleave that target specifically.
The shorter an arm is, the lower the degree of selectivity
and strength of annealing (annealing temperature) between
the arm and the target RNA. In converse, the longer an arm
is the more selective the annealing and the more heat is re-
quired to de-anneal the arm from the target RNA. Thus, it
may appear that the solution is to automatically give every
hhRz very long arms, but the catch is that longer single-
stranded arms make it more likely that an arm would an-
neal to itself and/or with the other arm (partially or fully).
Also, ribozymes with very long arms will anneal so strongly
to their target that they will not turnover to anneal to new
targets after cleavage.
In brief, the annealing temperature of a hhRz may be ap-
proximated by the sum of the annealing temperatures of
the two arms of the ribozyme. All environmental conditions
(e.g. ionic concentrations) being equal, the annealing tem-
perature is a function of the nucleotidemake-up and lengths
of the arms of a ribozyme. A number of formulas have
been used and compared (22,23) to calculate the annealing
temperature of RNA (and DNA) molecules, including the
fairly standard base-stacking approach employed by our al-
gorithm (adapted fromhttp://www.basic.northwestern.edu/
biotools/oligocalc.html (24)).
Since calculation of the annealing temperature is com-
putationally simple (relative to RNA folding) we use this
calculation in a discriminatory manner to weed out all can-
didate hhRz with arms that are too short or too long. In
fact, the range of acceptable annealing temperature we use
is from –5◦C to 60◦C above the temperature of the intended
environment for each for each arm separately. It is accept-
able for a single arm to have a lowTm if the other armmakes
up for it with a highly above average Tm. The exact val-
ues were determined by empirically testing many ranges to
avoid eliminating perfectly sound sequences.
For a given cut-site on a target RNA strand, the sequence
of any arm of a hhRz is dictated by the RNA sequence
around the cut-site, as a hhRz should anneal perfectly to its
target. Hence, every hhRz with target-matching arms and
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Figure 3. Partial snapshot of the input screen (step 2) for RiboSoft: allow-
ing for user specification of various parameters.
Figure 4. Snapshot of the input screen (step 3) for RiboSoft: confirmation
of user input.
an overall annealing temperature within the pre-specified
range is an acceptable hhRz candidate generated by this
phase of the design process.
Ribozyme structure
Every hhRz candidate surviving the annealing temperature
phase is evaluated for its structure. This is a measure of how
open (single-stranded) the arms are, which makes it easier
for a ribozyme to find and anneal to its intended target se-
quence and hence, perform its trans-cleavage function. The
Sfold program (25) is used on the server side to fold all the
candidates; it uses a statistical Boltzmann ensemble model
to generate possible secondary structures for the candidate
RNAs. Sfold reports 10 secondary structures, each with its
own probability. This probability is used as a weight when
considering the structure of a ribozyme.
RiboSoft gets the quality of one or many secondary
structures for one hhRz with an algorithm that uses the sum
of the melting temperatures of all continuous stretches of
double-stranded RNA as an (inverse) measure of the open-
ness of the two arms of the ribozyme. We allow up to one
mismatch in each ‘continuous’ stretch of double-stranded
RNA. All of the temperature values used are in Kelvin, as
cancelation may erroneously occur with negative tempera-
tures. A pseudo-code description can be found in supple-
mentary information.
For each secondary structure of the 10 secondary struc-
tures associated with a given hhRz, we compute one over-
all melting temperature. Naturally, continuous pairs in the
hhRz (Helix-II) will not be counted, since they are meant to
be there. However, a penalty of 50 degrees is added to any
structure lacking the hammerhead core, i.e. where the con-
served bases of the core are base paired or where Helix-II
is not formed. Since the resultant temperature here is asso-
ciated with only one of 10 possible structures, a weighted
sum (Qf) of all 10 temperatures is calculated, for each hhRz
candidate, using the formula:
Q f =
∑
i∈Q fs · Qs (2)
whereQs is the melting temperature of one secondary struc-
ture; fs is the probability associated with that secondary
structure; Q is the set of all 10 structures. Naturally, lower
values forQf are preferred and as such, thismeasure of qual-
ity should be minimized.
Target accessibility
Accessibility is a measure of how easy it is to access the tar-
get. Targets that fold unto themselves strongly in the region
around and including a cut-site will reduce the efficiency of
a ribozyme designed for that cut-site.
Two accessibility terms are computed here. One term,
cut-site inaccessibility, inversely measures the openness of a
target cut-site, to a particular hhRz candidate with specific
arms’ lengths. This is reflected by the annealing temperature
of the region of the target cut-site, the region to which the
arms of a hhRz must anneal. The other term, disruption en-
ergy (Gdisruption) is based on research done by (26), and is in
fact: the free energy cost to melt any local secondary struc-
ture at the target site, making it accessible to hhRz binding.
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Figure 5. Sample output from RiboSoft. The cut-site number (starting at 0 for the first cut-site) and corresponding ribozyme sequence is shown for each
candidate. All the parameters corresponding to this candidate are shown on the same row, Tm of both arms, accessibility (from 0, worst, to 1, the best),
ribozyme shape (also from 0 to 1) and the overall rank. Off-target hits are shown only when the ribozyme was selected for in vivo use, 1 normally means
that only the targeted gene is hit, higher numbers imply potential non-specific activity.
The computation of cut-site inaccessibility is done per
candidate hhRz, as different ribozymes targeting the same
cut-site will have different arms’ lengths. The substrate is
also folded using Sfold, which returns 10 secondary struc-
tures for the cut-site region, hence 10 annealing temper-
ature values are computed for that region, and these are
summed using the probabilities of the corresponding sec-
ondary structures as weights. The result of this calculation is
the raw cut-site accessibility value (both cut-site inaccessibil-
ity and disruption energy are succinctly described in pseudo-
code, supplementary information).
The calculation of disruption energy is done per cut-site.
The reason for this is the significant computational cost as-
sociated with the computation of the secondary structure
for a long RNA strand; typical gene transcripts are one
to several thousand bases long. We use 23 bases for both
arms’ binding sites and hence computeGdisruption. This al-
lows the evaluation of the structures likely to compete most
strongly with hhRz binding. Since Sfold returns 10 possible
secondary structures for the target transcript, we will also
have 10 Gdisruption values. These values are used to calcu-
late a weighted linear sum in a fashion identical to what was
done for cut-site accessibility.
As with ribozyme structure, cut-site inaccessibility and
disruption energy should be minimized. In other words, Ri-
boSoft looks both at the ease with which the ribozyme can
bind to the target site, as well as the structure of hhRz and
target.
Specificity assessment
For in vivo applications it is important that a given ribozyme
affects the targeted transcript and no other. Typically, a
hhRz would affect a transcript by cleaving it. It is possible,
however, for a hhRz to anneal to a transcript and hence,
lead to the transcript’s destruction or to a reduction in its
translational efficiency, without cleaving it. This is part of
what is known as off-target effects. Hence, the ‘advanced
options’ section of RiboSoft’s input pages allow the user to
check for either off-target hits that would potentially result
in cleavage or all off-target hits, including those that do not
lead to cleavage.
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The NCBI BLAST web-service is queried with a high
threshold (sensitivity) using the region around the targeted
cut-site corresponding to the maximal possible lengths of
hhRz arms. The results are weighted based on the number
of matched pairs, thus a perfect match yields a weight of
one (the targeted transcript). It should be noted that RNAs
with accession numbers startingwithXMorXR (RNApre-
dicted sequences) are ignored in the count, but are still re-
ported in the results’ page.
The programwill only return 0 if the RNA sequence does
not exist, since there is not necessarily a priori knowledge
of the transcript being targeted (users can enter arbitrary
sequences directly). Optimally, the value of specificity is 1,
entailing a perfect match to only one cut-site on the targeted
transcript. Higher specificity values are detrimental to the
quality of the hhRz candidate, and as such this measure of
quality should beminimized (pseudo-code in supplementary
information briefly describes this).
Hammerhead ribozymes
The hammerhead DNA templates, recommended
by RiboSoft for PABPN1, were prepared by 5 cy-
cles of polymerase chain reaction (PCR) using Taq
DNA polymerase and 1 M of the T7 promoter 5′-
TAATACGACTCACTATAGCG-3′ with 1 M of each
oligonucleotide (sequences complementary to the T7
promoter are underlined):
5′-GGCCTGGAGTTTCGTCGCATTTCA
GCGACTCATCAGTGAGGTTAAACTGGAG
CCTGCGCTATAGTGAGTCGTATTA-3′, 5′-
TATCAAAGCTCGAGTTTCGTCGCATTTC
AGCGACTCATCAGAGGGATTAGATGGAG
GAAGACGCTATAGTGAGTCGTATTA-3′,
5′-AGATGAATATGAGTTTCGTCGCATTT
CAGCGACTCATCAGCACCTTTACCAG
GCAATGCGCTATAGTGAGTCGTATTA-3′,
5′-GGGTCGCGTTTCGTCGCATTTCAG
CGACTCATCAGTACAGTTAGGGCC
GGCGCTATAGTGAGTCGTATTA-3′.corresponding
respectively to the constructions for Yz144, Yz363, Yz437
and Yz867, with an annealing temperature of 55◦C with
200 M dNTP, 2 mM MgCl2, 120 mM Tris–HCl pH 8.8,
10 mM KCl, 10 mM (NH4)2SO4 and 0.1% Triton X-100.
The sizes of the DNA templates were confirmed on 1.5%
agarose gel. Full annotated ribozyme sequences, as well as
the target RNAs, are available in supplementary materials.
PABPN1 gene
The PABPN1 gene used to create by PCR the DNA tem-
plate for transcription was the D323 clone used in (16).
The first PCR product was made with the oligonucleotide
5′-GACTACGGGAACGGCCTGGAGTC-3′ starting 129
nucleotides downstream of the start codon and with the
oligonucleotide 5′-AAAGGGAACAAAAGCTGGAG-3′
147 nucleotides downstream of the stop codon (as reverse
complement); covering 936 nucleotides. To generate a full-
length PCR product, 20% betaine was incorporated to the
PCR reaction (same reaction conditions as above) for 30
cycles at an annealing temperature of 51◦C. A second PCR
reaction was performed on the first PCR product with iden-
tical conditions, except for the first oligonucleotide being
replaced by the oligonucleotide 5′-TAATACGACTCACT
ATAGCGACTACGGGAACGGCCTGGAGTC-3′ to in-
corporate the T7 promoter to the DNA template used for
transcription. The size of both DNA templates were con-
firmed on 0.7% agarose gel. The PCR product was purified
with an EZ-10 Spin Column PCRProducts PurificationKit
(Bio Basic Inc.) and precipitated in ethanol with NaOAc.
RNA synthesis of hammerhead ribozymes
Ribozymes were synthesized by in vitro run-off transcrip-
tion in 100 l reactions using 20 pmol of double-stranded
DNA template, 80 mM HEPES–KOH pH 7.5, 24 mM
MgCl2, 2 mM spermidine, 40 mM DTT, 3.0 mM of each
NTP, 0.01 U of yeast pyrophosphatase and 2 g of purified
T7RNApolymerase at 37◦C for 3 h (27). The reactionswere
stopped by adding 5 U of DNase (RNase free) and incubat-
ing at 37◦C for 30 min. The mixtures were extracted twice
with both phenol and chloroform, and the nucleic acid pre-
cipitated with ethanol. After dissolution in equal volumes
of water and formamide dye buffer (95% formamide, 10
mM EDTA, 0.025% bromophenol blue and 0.025% xylene
cyanol) the ribozymes were fractionated by 10% denaturing
(8 M urea) polyacrylamide gel electrophoresis (PAGE; 19:1
ratio of acrylamide to bisacrylamide) in buffer containing
45 mM Tris-borate pH 7.5 and 1 mM EDTA. The reaction
products were visualized by UV shadowing and the bands
corresponding to the ribozymes cut out. The transcripts
were eluted from the gel slices overnight at room tempera-
ture in a solution containing 0.1% SDS, 10 mM EDTA and
0.5 M ammonium acetate. The purified RNA was precipi-
tated by the addition of 0.1 volume of 2 M sodium acetate
pH 4.5 and 2.5 volumes of ethanol. After washing in 70%
ethanol and drying, the pellets were resuspended in ultra-
pure water, and the quantity of RNA determined by spec-
trophotometry at 260 nm.
RNA synthesis of PABPN1 gene
The full-length PABPN1 gene could not be transcribed ef-
ficiently. Various conditions and constructions were tested
until a constructionwith a truncated 5′-endwas successfully
transcribed at a reasonable amount. The ‘standard’ tran-
scription protocol described for the ribozymes was however
inefficient for this gene. Transcripts were obtained only with
the HiScribeTM T7 in vitro Transcription Kit (New England
Biolabs) where 50 pmol of the column-purified and precip-
itated DNA template was in presence of 20% betaine and
the kit’s supplied buffer, High Molecular Weight solution,
rNTPs and T7 RNA polymerase enzyme. The transcription
reaction proceeded for 4h30 at 42◦C and was stopped by
the addition of 5 U of DNase (RNase free) and incubating
at 37◦C for 45 min. Followed by phenol-chloroform extrac-
tion and precipitation, the RNA was purified on 5% 8 M
urea PAGE. Elution, precipitation and concentration deter-
mination were performed as stated above.
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RNA labeling
Purified PABPN1 RNA (6 pmol) was 5′ dephosphorylated
with 5U antarctic phosphatase in 50mMBis-Tris-Propane-
HCl pH 6.0, 1 mMMgCl2 and 0.1 mM ZnCl2 for 30 min at
37◦C followed by heat inactivation 5min at 65◦C. The RNA
was radioactively 5′-32P-labeled using 10 U of T4 polynu-
cleotide kinase (NEB) with 20 Ci of [ -32P]-ATP (3000
Ci/mmol; Perkin-Elmer) for 1 h at 37◦C in 70mMTris-HCl
pH 7.6, 10 mM MgCl2 and 5 mM DTT. The labeled RNA
was gel purified on 5% 8M urea PAGE, eluted, precipitated
as stated above except for the RNA bands being identified
by radioactivity rather than UV shadowing.
Kinetic measurements of ribozyme cleavage
Trace amount of [5′-32P]-radioactively labeled PABPN1
RNA and 10 nM of ribozyme (10 nM of each ribozymes
when in combination) were separately pre-incubated 10min
at 37◦C in the presence of cleavage buffer with ionic strength
roughly similar to physiological conditions (50 mMTris pH
7.5, 100 M MgCl2, 100 mM NaCl and 25 mM KCl). The
cleavage reaction was initiated by adding an equal volume
of target to the ribozyme. Aliquots (1.5 l) were removed at
intervals and the reaction terminated by addition to a 5 l
chilled mixture containing 95% (v/v) formamide, 10 mM
EDTA and electrophoresis dyes. Ribozyme and cleavage
products were separated by electrophoresis in a dual con-
centration 8 M urea 19:1 polyacrylamide gel with a 4% top
two-third and 20% bottom third. Gels were exposed to stor-
age phosphor screens, and quantified by phosphorimaging.
Proportion of cleavage was calculated by dividing the inten-
sity of bands corresponding to ribozyme cleavage products,
divided by the sum of all bands in the lane (including the
full length RNA). Progress curves were fitted by nonlinear
regression analysis to single exponential function.
Construction of plasmids for ribozyme expression in mam-
malian cells
The same four hhRz against PABPN1 were used, namely
Yz144, Yz363, Yz437 and Yz867. Templates containing
these hammerhead catalytic sequences were synthesized
chemically. The sequences of these four ribozymes are:
 Yz144: 5′ CAGGCTCCAGTTTAACCTCACTGATG
AGTCGCTGAAATGCGACGAAACTCCAGGCC 3′
 Yz363: 5′ TCTTCCTCCATCTAATCCCTCTGATG
AGTCGCTGAAATGCGACGAAACTCGAGCTT
TGATA 3′
 Yz437: 5′ GCATTGCCTGGTAAAGGTGCTGATGA
GTCGCTGAAATGCGACGAAACTCATATTCATC
T 3′
 Yz867: 5′ CCGGCCCTAACTGTACTGATGAGTCG
CTGAAATGCGACGAAACGCGACCC 3′
PCR products were digested with KpnI and Csp45I re-
striction endonucleases and were ligated with pUC-KE-
tRNA-CTE plasmids that had been digested with both
KpnI andCsp45I obtained kindly fromNawrot B. (19). The
DNA sequence of every plasmid was verified using Sanger
sequencing with the PCR primer P7 (5′-CGCCAGGGTT
TTCCCAGTCACGAC-3′).
Cell culture and transfection
Human transformed primary embryonal kidney cell lines
HEK293 were cultured in Dulbecco’s modification of Ea-
gle’s medium (Invitrogen), supplemented with 10% foetal
bovine serum, G418 (200 g/ml) was used as selection an-
tibiotic for ribozyme-transfected HEK293 cells. Cells were
grown in monolayer, at 37 ◦C in cell culture incubator with
5% CO2 in 6-well plates and transfected at 70–80% con-
fluence. Transfection with 2 g of the ribozyme contain-
ing plasmid was carried out using the Jet prime reagent
(Polyplus-transfection Inc., France) according to the manu-
facturer’s protocol. One week later, selected G418 cells were
collected for RNA and protein extractions in parallel.
Western blotting
Total proteins were extracted in SUB buffer at different
time points (containing 8M urea, 2% mercaptoethanol and
0.5% SDS), and electrophoresed in 12% SDS-PAGE gels.
Proteins were blotted into nitrocellulose membrane and
probed with specific antibodies against PABPN1 (1:2000)
(Abcam, USA). Parallel samples were probed using mon-
oclonal actin antibody (Chemicon International, USA) to
confirm the equal loading of lysates between lanes. After
incubation with specific secondary HRP-conjugated anti-
bodies, the membranes were revealed using the western blot
chemiluminescence reagent plus kit (NEN Life Sciences
Products, Boston, MA, USA).
Quantification of the band intensity was performed us-
ing the ImageJ software. Valueswere normalized by-actin.
Quantification of PABPN1 protein level was determined by
western blot using the ImageJ software, normalized to actin
and presented as fold change relative to the level of PABPN1
in untransfected HEK293T cells.
RESULTS
Fitness evaluation
The quality of a candidate ribozyme is reflected in all five
terms computed in sections above. It should be noted that
the raw values returned by some of those quality measures,
are not intuitively comprehensible. For instance, greater val-
ues for ribozyme structure indicate worse structures. In ad-
dition, it is often not clear what the lower and upper bounds
are, for a given measure. For these reasons, the following
equation is used to normalize the values returned by most
of the quality measures:
Mnormali zed = (Moriginal − Mmin)Mmax − Mmin (3)
whereMmin is the smallest value for that measure among all
candidates, and vice versa forMmax.Moriginal is the original
(raw) value for that measure, while Mnormalized is that value
after normalization. Also, if for a given measure larger val-
ues are detrimental, the following equation is applied to the
 at Institut Pasteur M
ediathÃ¨que Scientifique on August 16, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
e39 Nucleic Acids Research, 2016, Vol. 44, No. 4 PAGE 8 OF 12
output, so that 1 represents the best possible value and 0 the
worst:
Madjusted = 1 − Mnormali zed (4)
Mnormalized is the normalized value for that measure, while
Madjusted is that value inverted, and is the final value used by
the multi-objective optimization procedure outlined below.
Since melting temperature and specificity can be accurately
judged by the user, they are not normalized or adjusted.
Depending on the application, the designer will have a
greater interest in certain parameters versus others. For ex-
ample, specificity or lack of off-target effectsmay be of great
value to some in vivo applications, but would probably be
of no concern to most in vitro applications. Hence, it is not
possible to identify beforehand, and for all possible appli-
cations of a hhRz, what the relative importance of the vari-
ous terms should be. Even for a particular well-defined ap-
plication, it is sometimes impossible for a user to spell-out
numerically the relative importance of the various quality
terms. As such, we adopted a multi-objective optimization
approach to the ranking of the ribozymes.
This approach (summarized in supplementary material
and described in full in [28]) allows us to present the various
candidates to users, as members of various Pareto optimal
fronts. In other words, all ribozymes ranked 1 correspond
to an optimal choice between the parameters used by Ri-
boSoft such that choosing another candidate ribozymewith
one of these parameters ‘improved’ would actually lead to
a less efficient ribozyme due to other parameters being ad-
versely affected. This lesser candidate would be ranked as 2
with other such candidates ‘only one value away from the
optimum’, similarly, ribozymes ranked 3 would be less op-
timal than 2, and so on until all candidates not rejected by
RiboSoft cut-offs are ranked. In order for the user to make
a final decision as to the best hhRz for his application: both
rank and the various quality measures are included in a ta-
ble of all hhRz candidates. The table can be sorted, by the
user, according to any of the individual measures as well as
overall rank. This table constitutes the output of the web
service (RiboSoft) implementing the algorithm (Figure 5).
Additional details (including pseudo-code and examples of
results) are provided in supplementary information.
Single ribozyme cleavage and additive effect of combinations
In addition to specifying and devising a comprehensive
hhRz design algorithm, then implementing it as web ser-
vice, we have also used the service for a particular gene si-
lencing application. This involved the PABPN1 gene, whose
mutation results in a muscular dystrophy disease known as
OPMD. Before proceeding to in vivo trials in various model
organisms, which is a costly affair, we proceeded to test the
validity of ribozymes generated by RiboSoft, in vitro, for
their efficiency in cleaving the transcript (mRNA) of the
PABPN1 gene. The following two sections describe in de-
tail the wet lab experimental methods followed to test the
ribozymes and the results of these tests. The results were
positive and provide preliminary evidence of the value of
the new web service.
The in vitro efficiency of cleavage by the designed hhRz
of the PABPN1 transcript is shown in Figure 6. The exper-
Figure 6. Single and combined ribozyme cleavage. (A) The PABPN1 tran-
script is illustrated. Gray box corresponds to the region that includes the
mutations, but is not included in the transcript for this assay because we
were unable to fully transcribe it in vitro. White box corresponds to the
portion of the transcript used for the assay, with cleavage sites indicated.
(B) Cleavage assay. The 938 bases substrate labeled in 5′ was incubated 40
min at 37◦C, with 100 nM of the indicated ribozymes, in 50 mM Tris, pH
7.5, 100 mM NaCl and 100 M MgCl2, except for lane 1, which was in
0 MgCl2. Reactions were loaded on a 4% (top)/ 20% (bottom) denatur-
ing PAGE. Numbers with asterisks correspond to the labeled fragment.
The efficiency of cleavage, represented as a percentage of the original un-
cleaved transcript, is shown at the bottom of the figure. With the exception
of the first lane, the results are arranged, from left to right to reflect an in-
creasing number of participating ribozymes. Naturally, whatever remains
of the original transcript is represented by the bands at the top of the figure,
while the various fragments resulting from cleavage are spread all over the
gel below. The expected lengths of the transcript fragments are listed to the
left of the gel, while the actual lengths of the detected fragments are listed
on the right at the proper location. This gel is a representative experiment
of three assays.
iment measured the efficiency of cleavage of all single, dou-
ble, triple and quadruple combinations of four ribozymes.
We tested the efficiency of the ribozymes in conditions sim-
ilar to those often used to assay ribozymes intended for
use in mammalian cells (37◦C, 100 mM Na+ and 100 M
Mg2+). The only exception being the very first lane in Fig-
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ure 6, where a combination of all four ribozymes was used
at zero magnesium ion concentration.
The results indicate several important facts: (i) all sin-
gle ribozymes cleave the PABPN1 transcript, with an effi-
ciency of cleavage ranging between 39.3% and 81.5%. (ii)
A greater number of ribozymes invariably cleaves more ef-
ficiently than a smaller number of ribozymes; the average
cleavage percentage for 1, 2, 3 and 4 ribozymes is: 66.15%,
87.65%, 95.575% and 97.7%. (iii) Oddly enough, a combi-
nation of all four ribozymes in the absence of magnesium
ions also cleaved very efficiently (96.6%) even if magnesium
is thought to be essential for efficient cleavage by hhRz. (iv)
The greatest increase in the efficiency of cleavage resulted
from using two instead of one ribozyme. This result con-
firms that the design of the ribozymes, amongst many gen-
erated by RiboSoft, were correct, in that they led to func-
tional ribozymes.
To ensure the universal applicability of RiboSoft, we as-
sayed 15 additional hhRz designed by our software against
two very different targets, a RFP mRNA and a portion of
a 16S ribosomal RNA, the latter is notably structured and
likely much less accessible than the average mRNA. All the
ribozymes that were ranked 1 against these targets could
cleave similarly to the results obtained for PABPN1-hhRzs,
except for one inactive ribozyme, as well as most ribozymes
with ranks as low as 7 (Supplementary Figures S1, S2, Table
S1 and data not shown). However, for two ribozymes that
had poor rankings, and interestingly had an accessibility 2
measure of zero, no significant cleavage was observed (Sup-
plementary Table S1). Two hhRz based on the same cut-
sites, but designed manually, did not cleave either, providing
additional evidence that ‘good ranking hhRz’ designed by
RiboSoft warrant active ribozymes. As with PABPN1, the
combination of ribozymes led to nearly complete degrada-
tion of the substrate RNA (Supplementary Figure S1 and
S2).
Single and combined ribozymes kinetic reaction results
The progress of the cleavage reaction over time, for all com-
binations of the four ribozymes, is presented in Figure 7.
The purpose of these data is to see and mathematically
model the rate of the cleavage reaction. This allows us to
identify the time it takes the reaction to reach its steady-
state. The plots provide a complete picture of the dynamic
relationship between the number of ribozymes (participat-
ing in a reaction) and the rate of cleavage over time. The
efficiency of cleavage at each time step can be seen in Figure
7 as well as the constants of the cleavage rate (kobs).
It can be seen from the plots that both the rate of the
cleavage reaction and the steady-state value of cleavage effi-
ciency have increased due to the presence of an additional ri-
bozyme. The two-ribozyme combination was able to cleave
about 43% of the transcript in 10 min, while the single ri-
bozyme cleaved about 15% in the same time period. Also,
the two ribozyme combination had a steady-state cleavage
efficiency of ∼90% a clear improvement over the steady-
state of the single ribozyme of ∼ 30%. Similarly, the com-
bination of three ribozymes increased further the cleavage
efficiency of the RNA substrate. Indeed, only 5 min was re-
quired to cleave 44% of the target RNA, half as much time
Figure 7. Single and combined ribozyme kinetic. The rate of cleavage of
one, two, three and four combined ribozymes is illustrated. Cleavage was
quantified and plotted to determine rate constants, which are indicated
within the graph together with the final percentage of cleavage: open circle,
RNA substrate cleaved by a single ribozyme (Yz144); by two ribozymes
(Yz144 and Yz363); three ribozymes (Yz144, Yz363 and Yz437); and with
all ribozymes. Nine time points are taken at 0 s, 20 s, 40 s, 1 min, 2 min, 5
min, 10 min, 30 min and 1 h. These results are representative of two assays.
as with two ribozymes, which achieved 43% cleavage in 10
min. In spite of this, three ribozymes presented only aminor
improvement over the already highly efficient combination
of two ribozymes, 90% cleavage. No measurable improve-
ment was obtained with four ribozymes compared to three.
It is recommended that one uses two proven hhRz in gene
silencing applications; three or more hhRz is not advisable,
as that increases the cost of construction and delivery with-
out considerably enhancing the steady-state value of cleav-
age efficiency. Also, expressing many ribozymes increases
the likelihood of unwanted side-effects such as off-target
hits and toxicity for in vivo applications.
Specific hhRzs are able to inhibit PABPN1 expression level
To test the hhRzs silencing effect, we used the human cell
line HEK293T and transfected the cells with all differ-
ent hhRzs individually. Stable clones of hhRzs were main-
tained in G418 selective media all the time during manip-
ulations. We then performed western blot on cell extracts
to test the effectiveness of hhRzs in knocking down the en-
dogenous PABPN1 level in this cell line. Western blot re-
sults revealed hhRzs sequences: Yz144, and Yz437 as op-
timal candidates, as they showed high efficiency in knock-
down PABPN1 (Figure 8A). We then transfected combi-
nations of two hhRzs simultaneously in HEK293T cells
and performed western blot to test if they are more effec-
tive in knocking down PABPN1 protein level. A combina-
tion of two hhRzs showed more reduction in PABPN1 pro-
tein level (Figure 8B) than individual hhRzs (Figure 8A),
reducing expression down to 5% for the combinations of
Yz363 with either Yz437 or Yz144. In addition to provid-
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Figure 8. Ribozymes are effective in knocking down PABPN1. (A) Dif-
ferent individual ribozymes targeting PABPN1 transcript are able to
knock down the level of PABPN1 protein. The endogenous expression of
PABPN1 was analyzed by western blot. HEK 293T cells were transfected
with the corresponding individual ribozymes, and selected with G418 for
5 days before protein extraction. (B) Combination of two ribozymes tar-
geting PABPN1 transcript are more efficient in knocking down the level of
PABPN1 protein. The endogenous expression of PABPN1 was analyzed
by western blot. HEK 293 cells were transfected with the combined two
indicated hhRzs. For (A) and (B), the ‘control’ lanes correspond to plas-
mid without ribozymes. Actin antibodywas used to confirm equal loading.
The values below the gel indicate PABPN1 protein signal intensities (quan-
tified using ImageJ) after normalization to actin signal intensities and to
normal PABPN1 protein levels (in cells that have not been transfected).
ing a strong promoter, the pUC-KE-tRNA-CTE plasmid
includes a tRNA to help scaffold and export RNA to the
cytoplasm, as well as the Constitutive Transport Element
(CTE) which tethers an RNA helicase that helps unfold
RNA and facilitates hhRz binding to its target mRNA at
the same time. While concerns could arise from the use of
‘non-ribozyme’ sequence in the 5′ portion of the constructs,
this extra sequence is expected to fold in a modular fashion
independent from the hhRz. The excellent activity of the
ribozymes against their target in vivo confirms that the ri-
bozymes are still active.
DISCUSSION
This paper presents two main contributions to the world of
ribozyme design and ribozyme application. The first part
of the paper describes the algorithm and implementation
of RiboSoft, a completely automated program (offered as a
web service) for hhRz design. It can be used to design hhRz
to target any RNA sequence, including the transcript of any
gene. The program has clear and valuable advantages over
existing hammerhead design services, related to usability,
ribozyme quality assessment and multi-objective optimiza-
tion. It unifies in a single tool the functionalities of targeting
ribozyme design software that have been done in the last
decade: it finds target sites, computes target accessibility,
ribozyme structure validity and potential off-target effects.
More importantly for the future community of users, it pro-
vides a user friendly interface with the flexibility required
for any application: from in vitro assays, to gene targeting
in Escherichia coli, in humans or in any desired species and
computes all the complexity of the analysis to simply pro-
vide ribozymes that will likely be active over 90% of the time
as demonstrated by our in vitro assays.
A number of software exist to assist in ribozyme de-
sign. Up to now, the best tool in that regard was proba-
bly. Aladdin (SeArch computing tooL for hAmmerheaD
ribozyme DesIgN) (http://aladdin.ifc.cnr.it/aladdin). This
tool, which evolved from an earlier computational method
(29,30), is handy and scientifically sound. However, Ri-
boSoft has several advantages: it uses the latest research on
target-site accessibility; and it has off-target specificity anal-
ysis. Off-target accessibility could be evaluated with Ribo-
Substrates (31), but the design of ribozymes would then re-
quire the use of two different tools, which makes automated
design more complicated. RiboSoft also has the advantage
of allowing specification of the nature of the environment,
the type and size of the ribozyme and the nature of the ap-
plication. Similarly, the evaluation of possible hhRzs is eas-
ier with RiboSoft than Aladdin, because the former pro-
vides multi-objective ranking and allows sorting ribozymes
according to each parameter, Our experience with these pa-
rameters seem to point toward a stronger impact of ‘acces-
sibility 2’ on the ability of a chosen ribozyme to cleave its
target.
The other contribution is the design (byRiboSoft) of four
hhRz targeting the transcript of the PABPN1 gene, and test-
ing these ribozymes, in vitro and in vivo, for their cleavage
efficiency. A mutated PABPN1 is the root cause of OPMD
(oculopharyngeal muscular dystrophy) in humans, a late
onset muscle disease associated with progressive ptosis of
the eyelids, and dysphagia. The experiments validated the
designs as they demonstrated cleavage by each of the four
ribozymes. In spite of using single turnover conditions for
in vitro assays, the results in vivo show that the ribozymes
designed by RiboSoft lead to an efficient knockdown of
PABPN1. This is likely due to the use of a strong promoter
for ribozyme expression and higher stability of the struc-
tured ribozyme RNAs, as compared to the mRNA, which
generally have low expression as compared to most non-
coding RNAs. Overall, according to our results, we recom-
mend using two hhRzs for researchers interested in target-
ing a gene for silencing.
Any upcoming gene targeting projects can benefit from
RiboSoft which will easily provide multiple ribozyme de-
signs against any transcript. This fact will allow anyone to
select multiple ribozymes in order to attain the best effect
possible. Indeed, as we have demonstrated, a dramatic ad-
ditive effect is obtained by combining two ribozymes, and in
the few cases where it would be insufficient, three ribozymes
are likely to be enough, making RiboSoft all the more valu-
able.
There are two ways in which this work can be developed.
One direction is that of expanding the computational de-
sign tool to include not just hhRz, as it does now, but other
ribozymes, such as hairpin and HDV ribozymes. These ri-
bozymes share the basic architecture of a hhRz, which is
made of hybridizing arms responsible for the selective ca-
pability of the ribozyme and a largely conserved core. As
such, many ribozymes can, in principle, be optimized using
the same overall multi-objective approach employed by Ri-
boSoft, which essentially takes into account the (i) structure
of the ribozyme and exact sequence of its recognition arms;
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(ii) structure of the region of the targeted cut-site and its ex-
act sequence; (iii) off-target effects, for in vivo applications.
We cannot see any conceptual or technical impediments to
the customization of the general approach to the various
ribozymes whose functionality is a function of these three
(i–iii) sets of considerations.
In addition, riboswitch-ribozymes have been developed
and their use could be greatly extended with proper design
tools such as RiboSoft. A riboswitch is an RNA that turns
genes on or off, when it binds to a ligand input or a combi-
nation of ligand inputs (32). Riboswitches can be combined
with ribozymes so that the binding of their ligands trigger
RNA cleavage (33,34). Engineered examples of riboswitch-
ribozymes implementing Boolean functions include some
that respond to small-molecule ligands (14). Allosteric ri-
bozymes, or any other ribozyme, could be added to Ri-
boSoft in the same way as hhRzs have been implemented.
In the long run, users could choose from a list of ribozymes
with different features to target genes. In principle, any al-
losteric ribozymes found via SELEX (35) could be imple-
mented for future use, as long as their structures are known.
Although it was not packaged as a user friendly software
and was designed for self-cleaving ribozymes rather then
for ribozymes capable of cleaving any target, recently de-
veloped algorithms allowed construction of switchable ri-
bozymes based on the hhRz model and known aptamers
(36). This is similar towhat has been developed by the group
of Ronald Breaker in 2005, where a purely computational
approach was developed that found complementary RNA
ligands that altered the conformation and hence activity of
a hhRz (37). In fact, they tested in vitro computationally
designed ribozymes that implemented four Boolean logic
functions: AND,OR,NOTandYES. It is worth noting that
only a precisely delineated part of the ribozyme need to be
altered to give the whole ribozyme this unique allosteric ca-
pability; the rest of the ribozyme stays fixed. Both of these
allosteric ribozymes could be designed by a RiboSoft 2.0.
Another direction for development involves the modifi-
cation of the design of the resulting hhRz to test their gene
silencing functionality, as well as unwanted effects, in living
organisms. Selected ribozymes against PABPN1 appear to
cleave their target both in vitro and in vivo, which is promis-
ing for future work aiming to replace the mutant transcripts
with healthy mRNAs in human cell, thus advancing toward
a therapeutic approach to OPMD. Indeed, even when it is
theoretically possible to target them, the exact regions har-
boring mutations are not necessarily ideal cleavage sites.
However, addition of a healthy copy with sequence modifi-
cations rendering it immune to cleavage, as previously sug-
gested by others (38), allows the use of ribozymes for any
type of genes. In fact, even if many deleterious mutations
are known for numerous diseases, in such a model for gene
therapy it would be possible to target defective genes with-
out even knowing the exactmutations responsible of the dis-
ease.
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